AN2 Therapeutics, Inc. (ANTX) Income Annual - Discounting Cash Flows
ANTX
AN2 Therapeutics, Inc.
ANTX (NASDAQ)
Period Ending: LTM
(Last Twelve Months)
2024
12-31
2023
12-31
2022
12-31
2021
12-31
2020
12-31
2019
12-31
Report Filing 2025-05-13 2025-03-25 2024-03-29 2023-03-29 2021-12-31 2020-12-31 2019-12-31
Revenue 0 0 0 0 0 0 0
Cost of Revenue 0 0 0 0 0 0 0
Gross Profit 0 0 0 -0.077 0 0 0
Operating Expenses 50.03 54.55 69.64 42.19 21.57 7.28 5.18
Research & Development 33.52 40.49 54.87 29.51 16.91 6.02 4.89
Selling, General and Administrative 14.27 14.07 14.76 12.75 4.67 1.26 0.289
Other Operating Expenses 2.23 0 0 -0.077 0 0 0
Operating Income -50.03 -54.55 -69.64 -42.26 -21.57 -7.28 -5.18
Net Non-Operating Interest 0.888 5.47 0 0.837 0.069 0.003 0
Interest Income 0.888 5.47 0 1.35 0.069 0.003 0
Interest Expense 0 0 0 0.514 0 0 0
Equity & Other Income/(Expense) 3.79 -2.23 4.9 0.469 -0.038 -6.32 -0.457
Income Before Tax -45.35 -51.32 -64.73 -40.96 -21.54 -13.6 -5.63
Income Tax Expense 0 0 0 0.514 -0.069 -0.003 -0.031
Income Attributable to Non-Controlling Interest 0 0 0 -0.514 0.069 0.003 0.031
Net Income -45.35 -51.32 -64.73 -40.96 -21.54 -13.6 -5.63
Depreciation and Amortization 10.85 0 69.64 0.077 21.57 7.28 31.07
EBITDA -39.18 -54.55 0 -42.19 0 0 25.89
Earnings Per Share (EPS) -1.51 -1.72 -2.74 -2.79 -1.55 -0.97 -0.3
Diluted Earnings Per Share -1.51 -1.72 -2.74 -2.79 -1.55 -0.97 -0.3
Weighted Average Shares Outstanding 30.05 29.83 23.6 15.34 18.74 18.74 18.74
Diluted Weighted Average Shares Outstanding 30.05 29.83 23.6 15.34 18.74 18.74 18.74
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us